RADIOLABELED 5-HT6 LIGANDS
Compounds of formula (I) are disclosed Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by 5-HT 6 receptor ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as 5-HT 6 positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
1 . A compound of formula (I),
or a pharmaceutically acceptable salt, ester, amide, prodrug, or radiolabeled form thereof, wherein
R is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and C 3 -C 8 cycloalkyl.
2 . The compound of claim 1 , wherein said compound comprises a radiolabel.
3 . The compound of claim 1 , wherein R comprises a radiolabel.
4 . The compound of claim 1 , wherein R is hydrogen.
5 . The compound of claim 1 , wherein R is C 1 -C 6 alkyl.
6 . The compound of claim 5 , wherein R is 11 CH 3 .
7 . The compound of claim 5 , wherein R is 11 CH 2 CH 3 .
8 . The compound of claim 5 , wherein R is 11 CH 2 CH 2 CH 3 .
9 . The compound of claim 5 , wherein R is CH 2 CH 2 18 F.
10 . The compound of claim 5 , wherein R is CH 2 CH 2 CH 2 18 F.
11 . The compound of claim 5 , wherein R is C 1 -C 6 hydroxyalkyl.
12 . The compound of claim 5 , wherein R is —CO 2 tBu.
13 . The compound of claim 1 , selected from the group consisting of:
8-(piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-methylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-ethylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-propylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-(2-fluoroethyl)piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-(3-fluoropropyl)piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
2-(4-(3-(pyridin-2-ylsulfonyl)quinolin-8-yl)piperidin-1-yl)ethanol;
3-(4-(3-(pyridin-2-ylsulfonyl)quinolin-8-yl)piperidin-1-yl)propan-1-ol;
tert-butyl 4-(3-(pyridin-2-ylsulfonyl)quinolin-8-yl)piperidine-1-carboxylate;
8-(1-[ 11 C]methylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-[1- 11 C]ethylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-[1- 11 C]propylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-(2-[ 18 F]fluoroethyl)piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-(3-[ 18 F]fluoropropyl)piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline; and
8-(1-([ 3 H]methyl)piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline.
14 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt, ester, amide, prodrug, or radiolabeled form thereof, in combination with a pharmaceutically acceptable carrier.
15 . Use of a compound of claim 1 as a 5-HT 6 positron emission tomography ligand.
16 . The use of claim 15 , wherein the compound is selected from the group consisting of:
8-(1-[ 11 C]methylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-[1- 11 C]ethylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-[1- 11 C]propylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-(2-[ 18 F]fluoroethyl)piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline;
8-(1-(3-[ 18 F]fluoropropyl)piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline; and
8-(1-([ 3 H]methyl)piperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline.
17 . The use of claim 16 , wherein the compound is 8-(1-[ 11 C]methylpiperidin-4-yl)-3-(pyridin-2-ylsulfonyl)quinoline.
18 . A method for imaging 5-HT 6 receptors in a mammal comprising administering to a subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, ester, amide, prodrug, or radiolabeled form thereof.
19 . A method of treating or preventing a condition or disorder selected from the group consisting of deficits in memory and cognition and learning, Alzheimer's disease, age-related cognitive decline, mild cognitive impairment, attention deficit/hyperactivity syndrome, schizophrenia, cognitive deficits of schizophrenia, depression, anxiety, obsessive compulsive disorders, Parkinson's disease, epilepsy, migraine, sleep disorders, anorexia, bulimia, irritable bowel syndrome, stroke, spinal or head trauma and head injuries, drug addition, and obesity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt, ester, amide, prodrug, or radiolabeled form thereof.